Skip to main content

Table 2 Biomarkers determination

From: Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

  Primary tumor (n = 70) Metastases (n = 49) Clinical practicea (n = 102)
No. (%) No. (%) No. (%)
ER status
  < 1% 3 (4.3) 0 2 (2.0)
  ≥ 1% 65 (92.9) 49 (100) 100 (98.0)
 Unknown 2 (2.8) 0 0
PgR status
  < 1% 10 (14.3) 12 (24.5) 22 (21.6)
  ≥ 1% 58 (82.9) 37 (75.5) 80 (78.4)
 Unknown 2 (2.8) 0 0
Ki67 status
  < 20% 39 (55.7) 30 (61.2) 63 (61.8)
  ≥ 20% 27 (38.6) 17 (34.7) 38 (37.2)
 Unknown 4 (5.7) 2 (4.1) 1 (1)
HER2 status
 Negative 57 (81.4) 41 (83.7) 88 (86.3)
 Positive 10 (14.3) 7 (14.3) 14 (13.7)
 Unknown 3 (4.3) 1 (2) 0
AR status
  < 1% 5 (7.1) 12 (24.5) 17 (16.7)
  ≥ 1% 65 (92.9) 37 (75.5) 85 (83.3)
  < 10% 7 (10.0) 19 (38.8) 26 (25.5)
  ≥ 10% 63 (90.0) 30 (61.2) 76 (74.5)
  1. Abbreviation: ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
  2. abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed